JP2023506842A5 - - Google Patents

Info

Publication number
JP2023506842A5
JP2023506842A5 JP2022536699A JP2022536699A JP2023506842A5 JP 2023506842 A5 JP2023506842 A5 JP 2023506842A5 JP 2022536699 A JP2022536699 A JP 2022536699A JP 2022536699 A JP2022536699 A JP 2022536699A JP 2023506842 A5 JP2023506842 A5 JP 2023506842A5
Authority
JP
Japan
Prior art keywords
sequence
pharmaceutical composition
molecule
wiz
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022536699A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023506842A (ja
JP7846007B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/001098 external-priority patent/WO2021123920A1/en
Publication of JP2023506842A publication Critical patent/JP2023506842A/ja
Publication of JP2023506842A5 publication Critical patent/JP2023506842A5/ja
Priority to JP2026060998A priority Critical patent/JP2026126214A/ja
Application granted granted Critical
Publication of JP7846007B2 publication Critical patent/JP7846007B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022536699A 2019-12-18 2020-12-16 異常ヘモグロビン症の治療用組成物及び方法 Active JP7846007B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026060998A JP2026126214A (ja) 2019-12-18 2026-04-02 異常ヘモグロビン症の治療用組成物及び方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962950025P 2019-12-18 2019-12-18
US201962950048P 2019-12-18 2019-12-18
US62/950,048 2019-12-18
US62/950,025 2019-12-18
PCT/IB2020/001098 WO2021123920A1 (en) 2019-12-18 2020-12-16 Compositions and methods for the treatment of hemoglobinopathies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026060998A Division JP2026126214A (ja) 2019-12-18 2026-04-02 異常ヘモグロビン症の治療用組成物及び方法

Publications (3)

Publication Number Publication Date
JP2023506842A JP2023506842A (ja) 2023-02-20
JP2023506842A5 true JP2023506842A5 (cg-RX-API-DMAC7.html) 2024-10-16
JP7846007B2 JP7846007B2 (ja) 2026-04-14

Family

ID=74701511

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022536699A Active JP7846007B2 (ja) 2019-12-18 2020-12-16 異常ヘモグロビン症の治療用組成物及び方法
JP2026060998A Pending JP2026126214A (ja) 2019-12-18 2026-04-02 異常ヘモグロビン症の治療用組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026060998A Pending JP2026126214A (ja) 2019-12-18 2026-04-02 異常ヘモグロビン症の治療用組成物及び方法

Country Status (5)

Country Link
US (1) US20230279394A1 (cg-RX-API-DMAC7.html)
EP (1) EP4077676A1 (cg-RX-API-DMAC7.html)
JP (2) JP7846007B2 (cg-RX-API-DMAC7.html)
CN (1) CN115176005A (cg-RX-API-DMAC7.html)
WO (1) WO2021123920A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250179531A1 (en) * 2022-02-25 2025-06-05 Vor Biopharma Inc. Compositions and methods for homology-directed repair gene modification
CN116445402B (zh) * 2023-05-09 2025-04-25 中国科学院生态环境研究中心 红系祖细胞的扩增培养基、扩增培养方法及应用
US12385408B1 (en) * 2024-01-26 2025-08-12 Rtx Corporation Life and performance improvement trenches

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800815A (en) 1903-05-05 1998-09-01 Cytel Corporation Antibodies to P-selectin and their uses
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US6309639B1 (en) 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
ATE237353T1 (de) 1992-05-05 2003-05-15 Aeres Biomedical Ltd Antikörper gegen p-selectin und ihre verwendung
US5622701A (en) 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
TW589189B (en) 1997-08-04 2004-06-01 Scras Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
AU776150B2 (en) 1999-01-28 2004-08-26 Medical College Of Georgia Research Institute, Inc. Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
JP2004532616A (ja) 2000-12-28 2004-10-28 ジョンソン・アンド・ジョンソン・リサーチ・ピー・ティー・ワイ・リミテッド 二本鎖rna仲介遺伝子抑制
AU2004305111B2 (en) 2003-12-19 2011-04-28 Novartis Vaccines And Diagnostics, Inc. Cell transfecting formulations of small interfering RNA, related compositions and methods of making and use
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
PL2662091T3 (pl) 2006-12-01 2019-05-31 Novartis Ag Przeciwciała skierowane przeciwko selektynie P i sposoby ich zastosowania do leczenia chorób zapalnych
US8945565B2 (en) 2006-12-01 2015-02-03 Selexys Pharmaceuticals Corporation Methods of treating inflammatory or thrombotic conditions with anti-P-selectin antibodies
US20110212096A1 (en) 2006-12-01 2011-09-01 Scott Rollins Anti-p-selectin antibodies and methods of their use and identification
WO2009108274A2 (en) * 2008-02-26 2009-09-03 The University Of North Carolina At Chapel Hill Methods and compositions for adeno-associated virus (aav) with hi loop mutations
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
WO2011076807A2 (en) 2009-12-23 2011-06-30 Novartis Ag Lipids, lipid compositions, and methods of using them
CN103153284B (zh) 2010-07-06 2015-11-25 诺华股份有限公司 含有其pKa值有利于RNA递送的脂质的脂质体
EP3542789A3 (en) 2010-08-31 2020-01-01 GlaxoSmithKline Biologicals SA Lipids suitable for liposomal delivery of protein-coding rna
RU2014104090A (ru) 2011-07-06 2015-08-20 Новартис Аг Липосомы с эффективным соотношением n:p для доставки молекул phk
WO2013059343A1 (en) 2011-10-17 2013-04-25 Massachusetts Institute Of Technology Intracellular delivery
US9394547B2 (en) 2012-01-03 2016-07-19 City University Of Hong Kong Method and apparatus for delivery of molecules to cells
US20130178421A1 (en) 2012-01-06 2013-07-11 Alcon Research, Ltd. Interfering rna delivery system and uses thereof
SI2807165T1 (sl) 2012-01-27 2019-08-30 Universite De Montreal Pirimido(4,5-B)indol derivati in njihova uporaba pri ekspanziji hematopoetskih matičnih celic
BR112014020325A2 (pt) * 2012-02-17 2017-08-08 Childrens Hospital Philadelphia composições de vetor do aav e métodos para a transferência de gene para as células, órgãos e tecidos
US10227610B2 (en) 2013-02-25 2019-03-12 Sangamo Therapeutics, Inc. Methods and compositions for enhancing nuclease-mediated gene disruption
ES2887254T3 (es) 2013-03-08 2021-12-22 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
EP2968295A1 (en) 2013-03-15 2016-01-20 Global Blood Therapeutics, Inc. Compositions and methods for the modulation of hemoglobin (s)
PL2970948T3 (pl) 2013-03-15 2019-06-28 Glaxosmithkline Biologicals Sa Sposoby oczyszczania rna
US10124336B2 (en) 2013-08-16 2018-11-13 Massachusetts Institute Of Technology Selective delivery of material to cells
US10426737B2 (en) 2013-12-19 2019-10-01 Novartis Ag Lipids and lipid compositions for the delivery of active agents
US10059655B2 (en) 2013-12-19 2018-08-28 Novartis Ag Lipids and lipid compositions for the delivery of active agents
EP3129485B2 (en) * 2014-04-09 2022-12-21 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating cystic fibrosis
WO2018071871A1 (en) 2016-10-13 2018-04-19 President And Fellows Of Harvard College Compositions and methods for non-myeloablative conditioning
US20180135080A1 (en) * 2016-11-15 2018-05-17 Genomic Vision Sa Method for the monitoring of modified nucleases induced-gene editing events by molecular combing
US20180305719A1 (en) * 2017-04-19 2018-10-25 The Board Of Trustees Of The University Of Illinois Vectors For Integration Of DNA Into Genomes And Methods For Altering Gene Expression And Interrogating Gene Function
EP3731849A4 (en) * 2017-12-28 2021-12-01 Codiak BioSciences, Inc. EXOSOME FOR IMMUNONCOLOGICAL AND ANTI-INFLAMMATORY THERAPY
US20190345516A1 (en) * 2018-03-12 2019-11-14 Musc Foundation For Research Development Methods for treating eye disease

Similar Documents

Publication Publication Date Title
AU2019226001B2 (en) CAMK2D antisense oligonucleotides and uses thereof
US11932856B2 (en) RNA targeting of mutations via suppressor tRNAs and deaminases
US10369232B2 (en) Allele selective gene editing and uses thereof
AU2017219605A1 (en) Excision of retroviral nucleic acid sequences
WO2015153791A1 (en) Crispr/cas-related methods and compositions for treating herpes simplex virus type 2 (hsv-2)
JP7546295B2 (ja) ヒトアンジェルマン症候群において父方ube3a遺伝子発現を復活させるための組成物および方法
RU2018137677A (ru) Модифицированная промоторная система u6 для тканеспецифической экспрессии
EP3758714A1 (en) Methods and compositions for treating angelman syndrome
US12351836B2 (en) Microhomology mediated repair of microduplication gene mutations
JP2024119830A5 (cg-RX-API-DMAC7.html)
CN113994009B (zh) 用于修饰scn9a或scn10a基因的基因编辑系统及其使用方法
US20200263206A1 (en) Targeted integration systems and methods for the treatment of hemoglobinopathies
JP2021525531A5 (cg-RX-API-DMAC7.html)
JP2021534796A5 (cg-RX-API-DMAC7.html)
AU2017231865B2 (en) Allele-specific gene suppression
CA3238629A1 (en) Methods for intratumoral delivery of crispr/cas systems
JP2022548320A (ja) アポリポタンパク質b(apob)遺伝子発現をモジュレートするための組成物および方法
US20230332150A1 (en) shRNA TARGETING SNORD115 LOCATIONS TO RESTORE PATERNAL UBE3A GENE EXPRESSION IN ANGELMAN SYNDROME
KR20230123926A (ko) Dlx2 벡터
CN115916975A (zh) 靶向mitf基因的核酸分子及其用途
CA3017326C (en) Allele-specific gene suppression
WO2025196338A1 (en) Methods and compositions for the treatment of autosomal dominant polycystic kidney disease
WO2024254244A2 (en) RNAi TARGETING HNRNPH2 MISSENSE MUTATIONS FOR TREATMENT OF BAIN SYNDROME
CN121335979A (zh) 靶向hbg1和hbg2的组合物及其使用方法
WO2026035995A1 (en) Compositions and methods for switched-on adar-edited rna (sonar) sensor